-
Barcelona, Liverpool, Bayern and Atletico reach Champions League quarter-finals
-
Tudor impressed by 'improved' Spurs despite Champions League exit
-
PSG will not relish Liverpool reunion, says Slot
-
Kane says Bayern 'don't fear anyone' ahead of Real clash
-
Venezuelan leader sacks defense minister, a Maduro stalwart
-
Kane and Bayern swat aside Atalanta to set up Real clash
-
Thailand's new parliament set to elect Anutin as PM
-
Atletico survive Spurs scare to reach Champions League quarters
-
Liverpool thrash Galatasaray to reach Champions League quarters
-
Costa Rica cuts ties with Cuba, closes embassy in Havana
-
Music popstar will.i.am meshes AI and 'micromobility'
-
US Fed Chair says 'no intention' of leaving board while probe ongoing
-
Iran targets Gulf energy sites after intel chief killed
-
Colombia detains alleged mastermind of Ecuadoran candidate assassination
-
Costa Rica closes Havana embassy, tells Cuba to withdraw diplomats
-
NY's New Museum returns contemporary to heart of Manhattan
-
Cesar Chavez, icon of US labor movement, accused of serial sex abuse: report
-
Barcelona demolish Newcastle 7-2 to reach Champions League quarters
-
Trump nominee for Homeland Security chief grilled at fiery Senate hearing
-
First international aid convoy arrives in crisis-hit Cuba
-
Eight killed during Rio police operation, including drug kingpin
-
Iran suffers new blow as Israel kills intel chief
-
Slovakia curbs diesel sales, ups prices for foreigners
-
Oscar-winner Sean Penn meets troops in frontline Ukraine
-
Thousands rally in Istanbul to mark year since mayor's arrest
-
WNBA, players union agree 'transformative' labor deal: official
-
US Fed holds rates unchanged over 'uncertain' Iran war implications
-
Senegal govt calls for investigation into Cup of Nations decision
-
From Faraja to Sepah: Iran's multiple security forces
-
Billionaire Dyson buys 50 percent stake in Bath rugby
-
Senegal demands 'corruption' probe over AFCON decision as Morocco defend appeal
-
The platypus is even weirder than thought, scientists discover
-
PSG's Barcola ruled out for several weeks with ankle injury
-
Colombia detains suspect in 2023 killing of Ecuador politician
-
Iran condemned as UN maritime body holds emergency talks on Mideast shipping
-
Iraqi Kurdish shepherds stoic in face of yet another war
-
Iran women's football team return after asylum tussle
-
US launches new era of drug war with Latin American allies
-
How many cargo ships are passing Hormuz strait?
-
'Free France': Macron reveals name of Europe's largest warship
-
Oil surges as Iran gas facilities hit, stocks slide
-
Foreign press group slams Israeli police for breaking journalist's wrist
-
McIlroy happy with back injury recovery as Masters looms
-
Vinicius 'should be loved by everyone' says Donnarumma after celebration row
-
Iran was not rebuilding nuclear enrichment, US intelligence finds
-
Carrick urges England boss Tuchel to call up United trio
-
Three sporting champions to be stripped of titles for non-doping reasons
-
Chilean GDP beats 2025 forecast despite mining dip
-
Storms, warm seas drove sudden drop in Antarctic ice: study
-
Aston Villa want to be more than a 'maybe team' in quest for Europa League
US greenlights pig kidney transplant trials
Two US biotech companies say the Food and Drug Administration has cleared them to conduct clinical trials of their gene-edited pig kidneys for human transplants.
United Therapeutics along with another company, eGenesis, have been working since 2021 on experiments implanting pig kidneys into humans: initially brain-dead patients and more recently living recipients.
Advocates hope the approach will help address the severe organ shortage. More than 100,000 people in the United States are awaiting transplants, including over 90,000 in need of kidneys.
United Therapeutics's approval, announced Monday, allows the company to advance its technology toward a licensed product if the trial succeeds.
The study authorization was hailed as a "significant step forward in our relentless mission to expand the availability of transplantable organs," by Leigh Peterson, the company's executive vice president.
The trial will initially enroll six patients with end-stage renal disease before expanding to as many as 50, United Therapeutics said in a statement. The first transplant is expected in mid-2025.
Meanwhile, rival eGenesis said it had received FDA approval in December for a separate three-patient kidney study.
"The study will evaluate patients with kidney failure who are listed for a transplant but who face a low probability of receiving a deceased donor offer within a five-year timeframe," the company said.
Xenotransplantation -- transplanting organs from one species to another -- has been a tantalizing yet elusive goal for science.
Early experiments in primates faltered, but advances in gene editing and immune system management have brought the field closer to reality.
Pigs have emerged as ideal donors: they grow quickly, produce large litters, and are already part of the human food supply.
United Therapeutics said trial patients would be monitored for life, assessing survival rates, kidney function, and the risk of zoonotic infections -- diseases that jump from animals to humans.
Currently, there is only one living human recipient of a pig organ: Towana Looney, a 53-year-old from Alabama who received a United Therapeutics kidney on November 25, 2024.
She is also the longest-surviving recipient, having lived with a pig kidney for 71 days as of Tuesday. David Bennett of Maryland received a pig heart in 2022 and survived 60 days.
M.A.Colin--AMWN